NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01323400,Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST),https://clinicaltrials.gov/study/NCT01323400,PAZOGIST,COMPLETED,"The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib. This is a phase II, randomized, multicentre study.",NO,GIST,DRUG: Pazopanib|OTHER: Best supportive care,"Progression-free survival, Within 16 months after the first inclusion, from the date of randomisation until the date of the first documented progression or death from any cause","Overall survival, Within 16 months after the first inclusion, from the date of randomisation until the date of death from any cause|Objective tumour response rate (RECIST v.1.1) at 4 months, 4 months after randomisation|Best response (RECIST v.1.1) obtained during the study, Within 16 months after the first inclusion|Tolerance profile (NCI-CTCAE v.4.0), Within 16 months after the first inclusion|Pattern of progression-free survival in the different molecular subtypes, Within 16 months after the first inclusion, from the date of randomisation until the date of the first documented progression or death from any cause|Intra and inter-patient variability of the Cmin of pazopanib, After 4 weeks, 10 weeks, 16 weeks of pazopanib treatment and at time of progression|Progression-free survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression, Within 16 months after the first inclusion, from the date of the first pazopanib administration until the date of the first documented progression or death from any cause|Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression, Within 16 months after the first inclusion, from the date of the first pazopanib administration until the date of death from any cause",,Centre Leon Berard,GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE2,81,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,PAZOGIST,2011-03,2014-04,2016-02,2011-03-25,,2016-02-25,"Institut Bergonié, Bordeaux, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, F-69008, France|Hôpital de la Timone, Marseille, France|Institut Paoli Calmette, Marseille, France|Centre Alexis Vautrin, Nancy, France|Institut de Cancérologie de l'Ouest, Nantes, France|Hôpital St Antoine, Paris, France|Hôpital Tenon, Paris, France|CHU de Reims, Reims, France|Institut Cancerologie Neuwirth, St Priest en Jarez, France|Institut Gustave Roussy, Villejuif, France",
